pharmashark.blogspot.com
PharmaShark: Novo's time to shine
http://pharmashark.blogspot.com/2010/01/novos-time-to-shine.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Novo's time to shine. Yesterday the FDA approved a potential blockbuster diabetes drug manufactured by Novo Nordisk. Read more about the approval and Victoza here. What happens when two big pharma companies merge? Well you get lots of job cuts and a bigger-than=necessary development pipeline. That's exactly what happened with Pfizer. Enter your email address:.
pharmashark.blogspot.com
PharmaShark: February 2010
http://pharmashark.blogspot.com/2010_02_01_archive.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Have a heart, it's V-Day! It's that time of year again.Valentine's Day! In honor of that, Seeking Alpha. Put together some nice data on 6 companies that work in the cardiac device market and in the website's opinion are making the right decisions. The basic take home message: Abbott and Edwards Life Sciences look like the strongest buys of the six. Reported ...
pharmashark.blogspot.com
PharmaShark: another IPO...
http://pharmashark.blogspot.com/2010/02/another-ipo.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. The Times reports here. And finally for some lighter reading:. Here's a nice piece by Fierce Biotech on the top 10 deals in 2009. And one from BNet on upcoming FDA decisions and happenings in the biotech world. Subscribe to: Post Comments (Atom). What's Going on at A New Box? Uarr; Grab this Headline Animator. There was an error in this gadget.
pharmashark.blogspot.com
PharmaShark: November 2009
http://pharmashark.blogspot.com/2009_11_01_archive.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Zetia down, out? Next up, is this really news? Almost every vaccine manufacturer has conducted trials on cell-based production technology, but there has been little to no regulatory progress on them yet. Read the WSJ piece for yourself. Read more from the BBC here. Read more on the IPO here. Speaking of IPO's.Cumerland, which held its own IPO earlier thi...
pharmashark.blogspot.com
PharmaShark: Time's Up!
http://pharmashark.blogspot.com/2010/02/times-up.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Everyone's talking about the upcoming patent cliff next year.well the downward slope towards the edge starts this year:. See this nifty little article by Fierce Pharma on the patent expirations for 2010. While that patent cliff is enough to turn investors white, Elan. Reuters reports here on the profit projection. Reuters discusses Crucell here. Have a heart...
pharmashark.blogspot.com
PharmaShark: Tysabri Back in the News
http://pharmashark.blogspot.com/2010/02/tysabri-back-in-news.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Tysabri Back in the News. Read the FDA advisory here. Read more at NJ.com. Optimer has created a new antibiotic for the common bacteria C.diff that seems to be at least as effective as a commonly used treatment for the potentially lethal infection. What does this mean for Optimer? Xconomy offers insight here. Subscribe to: Post Comments (Atom).
pharmashark.blogspot.com
PharmaShark: AZ drops the ax
http://pharmashark.blogspot.com/2010/01/az-drops-ax.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. AZ drops the ax. Read more in the UK publication, the Telegraph. It's usually small biotechs that make news when they announce plans to go public. This time though, it's a bit different as Otsuka. The Reuters article is here. Subscribe to: Post Comments (Atom). What's Going on at A New Box? Uarr; Grab this Headline Animator. There was an error in this gadget.
pharmashark.blogspot.com
PharmaShark: Have a heart, it's V-Day!
http://pharmashark.blogspot.com/2010/02/have-heart-its-v-day.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Have a heart, it's V-Day! It's that time of year again.Valentine's Day! In honor of that, Seeking Alpha. Put together some nice data on 6 companies that work in the cardiac device market and in the website's opinion are making the right decisions. The basic take home message: Abbott and Edwards Life Sciences look like the strongest buys of the six.
pharmashark.blogspot.com
PharmaShark: The Day After...
http://pharmashark.blogspot.com/2010/02/day-after.html
Not so detailed news/notes/analysis of happenings in the pharma/biotech/clinical research realm.a chip off the New Box. Brought to you by A New Box. Read more here in Xconomy. Read more here fromhttp:/ www.reuters.com/article/idUSN0313639620100203. The answer is that Teva is treating its drug as a entirely new product with a new BLA.interesting idea. If the FDA looks favorably on this new biologic, expect Teva to pull in some serious cash. Fierce Biotech reports on the situation here. Head to head trials.